Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Disaggregation of Revenue [Line Items]
Net sales	$ 3,745.9	$ 3,569.0	$ 7,255.6	$ 6,812.2
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,418.4	2,284.5	4,750.9	4,401.4
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,327.5	1,284.5	2,504.7	2,410.8
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	452.2	387.9	914.2	775.9
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	200.2	182.7	410.2	355.0
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	129.2	136.8	230.3	233.5
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	120.6	128.1	241.2	240.7
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	112.9	100.3	207.9	198.8
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	97.4	91.4	194.8	173.8
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	76.4	70.0	143.5	133.4
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	66.7	63.1	128.7	122.4
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	71.4	61.1	144.0	121.3
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	38.8	40.7	78.0	77.8
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	70.7	66.6	133.2	124.9
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	39.8	48.4	77.1	91.2
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	39.4	41.6	73.4	74.9
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	38.1	33.9	72.9	66.2
Developed Markets Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	1,122.3	1,121.4	2,191.3	2,141.2
Developed Markets Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	1,071.4	997.9	2,023.2	1,869.8
Greater China \| Brands
Disaggregation of Revenue [Line Items]
Net sales	710.8	586.5	1,388.0	1,139.3
Greater China \| Generics
Disaggregation of Revenue [Line Items]
Net sales	3.0	2.4	5.9	5.1
Japan, Australia and New Zealand Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	144.1	160.5	283.2	302.3
Japan, Australia and New Zealand Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	152.0	145.2	286.3	279.5
Emerging Markets Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	441.2	416.1	888.4	818.6
Emerging Markets Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	101.1	139.0	189.3	256.4
Operating Segment \| Developed Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	2,193.7	2,119.3	4,214.5	4,011.0
Operating Segment \| Greater China
Disaggregation of Revenue [Line Items]
Net sales	713.8	588.9	1,393.9	1,144.4
Operating Segment \| Japan, Australia and New Zealand Segment
Disaggregation of Revenue [Line Items]
Net sales	296.1	305.7	569.5	581.8
Operating Segment \| Emerging Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 542.3	$ 555.1	$ 1,077.7	$ 1,075.0